The MEK inhibitor Trametinib, an FDA-approved drug for the treatment of lung cancer, inhibits this downregulation of expression, blocks the conversion of microglia to a pro-tumor phenotype, and inhibits glioma growth (91). This evidence concerns the gene MAP2K7 and central nervous system cancer.